332 related articles for article (PubMed ID: 1406977)
1. New drug law to speed scientific review.
Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
[TBL] [Abstract][Full Text] [Related]
2. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
3. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
4. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
5. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
6. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
7. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
Bierut MB
Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
[No Abstract] [Full Text] [Related]
8. User fees for faster drug reviews. Are they helping or hurting the public health?
Thompson L
FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
[No Abstract] [Full Text] [Related]
9. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
10. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
11. FDA user fees approved.
Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
[No Abstract] [Full Text] [Related]
12. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
DerGurahian J
Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
[No Abstract] [Full Text] [Related]
13. User fees and beyond--the FDA Safety and Innovation Act of 2012.
Kramer DB; Kesselheim AS
N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
[No Abstract] [Full Text] [Related]
14. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
15. FDA user fees and innovation.
Somberg J
Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
[No Abstract] [Full Text] [Related]
16. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: FDA oversight.
; Berry MD
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
[No Abstract] [Full Text] [Related]
18. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
19. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
20. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
